Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

22.13 +1.38 (+6.65%)
Streaming Delayed Price Updated: 11:49 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.